Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07706179). This is a study registration, not published results. Lead sponsor: University of Wisconsin, Madison. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 10 participants (ESTIMATED). Conditions: HR+/HER2+ Breast Cancer, Metastatic Breast Cancer. Interventions: DRUG: Alisertib. Primary outcome measures: Clinical benefit defined as partial tumor response (PR) , 12 weeks; Clinical benefit defined as complete tumor response (CR) , 12 weeks; Clinical benefit defined as decline in circulating tumor DNA (ctDNA) , 12 weeks. Brief summary: The goal of this clinical trial is to learn if alisertib in addition to usual care works to treat HR+/HER2+ breast cancer. The main questions it aims to answer are: * Does alisertib stop the communication between HR and HER2? * Are there genetic markers that predict how well someone's cancer will respond to alisertib? Participants will receive alisertib in addition to their usual care.